Cargando…
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition to one of the following three criteria: overw...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669943/ https://www.ncbi.nlm.nih.gov/pubmed/37998750 http://dx.doi.org/10.3390/cimb45110573 |
_version_ | 1785149264109764608 |
---|---|
author | Filipovic, Branka Marjanovic-Haljilji, Marija Mijac, Dragana Lukic, Snezana Kapor, Suncica Kapor, Slobodan Starcevic, Ana Popovic, Dusan Djokovic, Aleksandra |
author_facet | Filipovic, Branka Marjanovic-Haljilji, Marija Mijac, Dragana Lukic, Snezana Kapor, Suncica Kapor, Slobodan Starcevic, Ana Popovic, Dusan Djokovic, Aleksandra |
author_sort | Filipovic, Branka |
collection | PubMed |
description | Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition to one of the following three criteria: overweight or obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. If the specific criteria are present, the diagnosis of MAFLD can be made regardless of alcohol consumption and previous liver disease. The pathophysiological mechanisms of MAFLD, including inflammation, lipotoxicity, mitochondrial disfunction, and oxidative stress, as well as the impact of intestinal gut microbiota, are constantly being elucidated. Treatment strategies that are continually emerging are based on different key points in MAFLD pathogenesis. Yet, the ideal therapeutic option has still not been found and future research is of great importance, as MAFLD represents a multisystemic disease with numerous complications. |
format | Online Article Text |
id | pubmed-10669943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106699432023-11-15 Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment Filipovic, Branka Marjanovic-Haljilji, Marija Mijac, Dragana Lukic, Snezana Kapor, Suncica Kapor, Slobodan Starcevic, Ana Popovic, Dusan Djokovic, Aleksandra Curr Issues Mol Biol Review Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition to one of the following three criteria: overweight or obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. If the specific criteria are present, the diagnosis of MAFLD can be made regardless of alcohol consumption and previous liver disease. The pathophysiological mechanisms of MAFLD, including inflammation, lipotoxicity, mitochondrial disfunction, and oxidative stress, as well as the impact of intestinal gut microbiota, are constantly being elucidated. Treatment strategies that are continually emerging are based on different key points in MAFLD pathogenesis. Yet, the ideal therapeutic option has still not been found and future research is of great importance, as MAFLD represents a multisystemic disease with numerous complications. MDPI 2023-11-15 /pmc/articles/PMC10669943/ /pubmed/37998750 http://dx.doi.org/10.3390/cimb45110573 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Filipovic, Branka Marjanovic-Haljilji, Marija Mijac, Dragana Lukic, Snezana Kapor, Suncica Kapor, Slobodan Starcevic, Ana Popovic, Dusan Djokovic, Aleksandra Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment |
title | Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment |
title_full | Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment |
title_fullStr | Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment |
title_full_unstemmed | Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment |
title_short | Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment |
title_sort | molecular aspects of mafld—new insights on pathogenesis and treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669943/ https://www.ncbi.nlm.nih.gov/pubmed/37998750 http://dx.doi.org/10.3390/cimb45110573 |
work_keys_str_mv | AT filipovicbranka molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT marjanovichaljiljimarija molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT mijacdragana molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT lukicsnezana molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT kaporsuncica molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT kaporslobodan molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT starcevicana molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT popovicdusan molecularaspectsofmafldnewinsightsonpathogenesisandtreatment AT djokovicaleksandra molecularaspectsofmafldnewinsightsonpathogenesisandtreatment |